ETElena A. Tomina

Elena A. Tomina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena A. Tomina has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Idiopathic pulmonary fibrosis: integration of modern diagnostic and therapeutic algorithms

    by A. A. Filippova, N. V. Lareva, E. V. Luzina, А. А. Zhilina, S. М. Tsvinger, Е. B. Zhigzhitova, Z. М. Zhigula, Е. А. Tomina, Е. S. Zaguzina

    Idiopathic pulmonary fibrosis (IPF) is a severe disease with an unfavorable prognosis, requiring a comprehensive, multidisciplinary approach to diagnosis and treatment. Its clinical presentation is dominated by nonspecific symptoms, primarily progressive dyspnea and cough, which clinicians may attribute to similar conditions (COPD, CHF, and others), thereby delaying verification of the diagnosis. Early diagnosis and the timely initiation of targeted therapy are crucial for improving patient outcomes. Antifibrotic medications (pirfenidone and nintedanib) are essential in IPF treatment, slowing pulmonary function decline and improving survival, particularly when initiated early. They exhibit comparable safety and efficacy profiles.

  • Open Access

    HELICOBACTER PYLORI INFECTION. RELEVANCE OF THE PROBLEM, PREVALENCE AND RISK FACTORS

    by E. V. Luzina, N. V. Lareva, L. B. Lazebnik, E. A. Tomina, O. A. Lyannaya

    Helicobacter pylori (HP) is one of the most common infections and is recognized as a gastric pathogen in humans, leading to the development of gastritis in all infected individuals. The etiological role of HP in the formation of peptic ulcer (PU) and gastric cancer (GC) has been noted. The prevalence of HP differs in different regions, in different ethnic, social and age groups. The article summarizes publications on the frequency of HP infection in different countries, changes in the epidemiological situation in the world in recent years, and noted a decrease in HP positivity in Japan, Korea, China, and Australia. Risk factors for infection were analyzed depending on gender, age, place of residence, ethnicity, educational status and profession. Data are presented on the more frequent infection of medical personnel with HP. Identification of an occupational risk group for medical workers is an important fact, as it can contribute to the early detection and treatment of Helicobacter pylori infection and associated diseases (chronic gastritis, ulcers, gastric cancer), the prevention and control of the transmission of HP in the workplace, as well as a better understanding of the problem and proper treatment of their patients.

  • Clinical case of high perinatal risk pregnancy with heterozygous Leiden mutation

    by Marina N. Mochalova, Anastasia G. Sidorkina, Elena S. Akhmetova, Tatyana V. Khaven, Lyubov A. Kuzmina, Olga A. Durova, Elena A. Tomina, Alexey V. Solpov, Victor A. Mudrov, Хавень Татьяна Васильевна

    This article presents the clinical case of hereditary thrombophilia associated with the heterozygous FV (Leiden) mutation. The patient was admitted to the hospital of the 3rd group with diagnosis: «Pregnancy 27 weeks 6 days. Burdened obstetric history. Scar on the uterus. Hereditary thrombophilia associated with a heterozygous mutation of factor V. The state of thrombotic readiness. Hypertension I stage, 1 degree, risk 1, controlled. Alimentary-constitutional obesity of the 1st degree. Endemic diffuse goiter of the 1st degree, euthyroidism. Chronic gastritis, remission.» On admission, the patient received Sol. Enoxaparini natrii at dosage of 0.4 ml subcutaneously 2 times every day, but according to the results of thrombodynamics, thrombotic readiness remained. The purpose of hospitalization was to select anticoagulant therapy. From the anamnesis, it was found that the woman's first pregnancy ended in operative delivery on time due to progressive severe premature detachment of a normally located placenta, intrapartum fetal death. Together with hematologists, the optimal anticoagulant therapy for this patient was selected: Sol. Enoxaparini natrii at dosage of 0.8 ml subcutaneously in the morning, then Sol. Enoxaparini natrii 0.4 ml subcutaneously in the evening, Tab. Acidi acetylsalicylici 0.15. Against the background of this therapy, positive dynamics was noted, normocoagulation was noted during the study of thrombodynamics. After the selection of anticoagulant therapy, the woman was discharged from the hospital under the supervision of an obstetrician-gynecologist of the antenatal clinic and the hematologist of the Clinical Medical Center. Antenatal hospitalization was planned for the period of 37 weeks. The patient was delivered by urgent caesarean section due to prenatal rupture of amniotic fluid at 35 weeks 1 day, given the aggravated anamnesis in patient with the uterine scar. A live premature girl was born weighing 2410 g, 44 cm tall and with an Apgar score of 8 and 8 points. In the postpartum period, given the high risk of thromboembolic complications, the patient was prescribed Enoxaparinum natrium at dosage of 0.4 ml subcutaneously 1 time per day for 6 weeks after delivery. The presented clinical case of pregnancy and childbirth demonstrates the importance of personalization in modern medicine.

  • Open Access

    Portal vein thrombosis — a literature review and our own clinical observations

    by E. V. Luzina, E. A. Tomina, S. I. Shchadneva, N. V. Lareva

    The portal vein thrombosis (PVT) is a partial or complete occlusion of blood flow through the portal vein that occurs due to the presence of a blood clot in its lumen. Currently, PVT has become more common in the clinic of internal diseases. PVT can be caused by many factors, among which local and systemic. Systemic factors include congenital and acquired thrombophilia. Local factors include inflammatory, infectious, and oncological diseases of the abdominal organs. One of the most likely causes of PVT is currently being considered liver cirrhosis. The article presents the literature data, clinical guidelines for managing patients with PVT in the discussion of three own clinical cases of patients with PVT, which were caused by various diseases.